Familial Primary Pulmonary Hypertension Market

Market Overview:

The 7 major familial primary pulmonary hypertension markets reached a value of US$ 5.1 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 8.2 Billion by 2034, exhibiting a growth rate (CAGR) of 4.32% during 2024-2034.

The familial primary pulmonary hypertension market has been comprehensively analyzed in IMARC's new report titled "Familial Primary Pulmonary Hypertension Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Familial primary pulmonary hypertension refers to a rare autosomal dominant illness characterized by distinctive alterations in pulmonary arterioles that lead to elevated pulmonary artery pressures, right ventricular failure, and eventually death. Individuals suffering from the ailment can experience a variety of indications, including shortness of breath (particularly during physical activity), fatigue, dizziness, chest pain, swelling in the ankles, legs, and abdomen, a bluish color in the lips and skin, a racing pulse or heart palpitations, etc. The diagnosis of familial primary pulmonary hypertension is typically based on a combination of the patient's symptoms, medical history, and a physical examination. An echocardiogram that relies on sound waves to produce images of the heart and aids in determining its functionality is also recommended. The healthcare provider may further conduct genetic testing to detect chromosomal irregularities and gene variations, contributing to the underlying indications among patients. Numerous imaging techniques, like chest X-rays, computed tomography scans, magnetic resonance imaging, etc., are utilized to evaluate abnormalities within the chest structures and rule out other possible health conditions.

The increasing cases of mutations in the genetic material, which is involved in controlling the growth and division of cells in the blood vessels, are primarily driving the familial primary pulmonary hypertension market. In addition to this, the inflating utilization of vasodilators, like calcium channel blockers, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, etc., to lower the elevated blood pressure in the pulmonary arteries and reduce the workload on the cardiac muscle is also creating a positive outlook for the market. Moreover, the widespread adoption of balloon atrial septostomy procedures, since they can alleviate the strain on the right ventricle by decompressing the right atrium and improving the balance between the two sides of the heart, is further bolstering the market growth. Apart from this, the emerging popularity of recombinant fusion protein therapy, which is designed to specifically target the underlying mechanisms or pathways associated with the disease to provide more effective and focused treatment compared to traditional therapies, is expected to drive the familial primary pulmonary hypertension market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the familial primary pulmonary hypertension market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for familial primary pulmonary hypertension and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the familial primary pulmonary hypertension market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the familial primary pulmonary hypertension market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the familial primary pulmonary hypertension market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current familial primary pulmonary hypertension marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the familial primary pulmonary hypertension market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the familial primary pulmonary hypertension market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the familial primary pulmonary hypertension market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of familial primary pulmonary hypertension across the seven major markets?
• What is the number of prevalent cases (2018-2034) of familial primary pulmonary hypertension by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of familial primary pulmonary hypertension by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with familial primary pulmonary hypertension across the seven major markets?
• What is the size of the familial primary pulmonary hypertension patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of familial primary pulmonary hypertension?
• What will be the growth rate of patients across the seven major markets?
   

Familial Primary Pulmonary Hypertension: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for familial primary pulmonary hypertension drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the familial primary pulmonary hypertension market?
• What are the key regulatory events related to the familial primary pulmonary hypertension market?
• What is the structure of clinical trial landscape by status related to the familial primary pulmonary hypertension market?
• What is the structure of clinical trial landscape by phase related to the familial primary pulmonary hypertension market?
• What is the structure of clinical trial landscape by route of administration related to the familial primary pulmonary hypertension market?